Literature DB >> 6208357

Pharmacokinetics of the poly-gamma-glutamyl metabolites of methotrexate in skin and other tissues of rats and hairless mice.

C L Zimmerman, T J Franz, J T Slattery.   

Abstract

The time course of methotrexate (MTX) and its poly-gamma-glutamyl metabolites (PGGs) was examined in the skin, liver and blood of rats and full-thickness skin, epidermis and blood of hairless mice to determine their contribution to the persistence of antifolate activity after a single dose of MTX. [3H]MTX was administered i.v. to rats and i.p. to mice in a dose similar, on a microgram per kilogram basis, to that administered to humans for the treatment of psoriasis. The animals were sacrificed at various times after the dose and skin and other tissues were analyzed for the presence of MTX and the PGGs. The percentage of total antifolates in the skin of rats that was attributable to the PGGs was less than 30% at all times examined (6 to 72 hr). However, more than half of the PGGs present contained three or more glutamic acid residues. The skin from the hairless mice was separated into dermis and epidermis to determine if MTX and its metabolites were present in the ostensible site of action in psoriasis, the epidermis (separation of epidermis from dermis is prohibited by hair in the rat). The PGGs accounted for less than 13% of total antifolates in full-thickness skin of mice at all times studied. The epidermis contained more antifolates, on a picomole per gram basis, at all times (4 to 24 hr) than did the full-thickness skin. In the epidermis, the percentage of total antifolates contributed by the PGGs rose to 35% by 24 hr, more than twice its value at earlier times.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208357

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

Review 2.  Molecular mechanism of methotrexate action in inflammation.

Authors:  B N Cronstein
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

3.  Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.

Authors:  R K Brazzell; P R Mayer; R Dobbs; P J McNamara; R L Teng; J T Slattery
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

4.  Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.

Authors:  Dong-Yang Liu; Hoi-Kei Lon; Yan-Lin Wang; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2013-04-07       Impact factor: 1.627

Review 5.  The practical use of methotrexate in psoriasis.

Authors:  J P Tung; H I Maibach
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

6.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

Authors:  B N Cronstein; D Naime; E Ostad
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.